An International Phase Ib Multicentre Study to Characterize the Safety and Tolerability of Intravenously Administered S64315 a Selective Mcl-1 Inhibitor, in Combination With Orally Administered Venetoclax a Selective Bcl-2 Inhibitor in Patients With Acute Myeloid Leukaemia

What is the purpose of this trial?

The purpose of this study is to determine the safety profile, tolerability and the Recommended Phase 2 Dose of the combination S64315 with venetoclax in patients with Acute Myeloid Leukaemia.



Institut de Recherches Internationales Servier (I.R.I.S.)

Start Date: 04/11/2019

End Date: 03/31/2022

Last Updated: 04/12/2019

Study HIC#: 2000024357

Get Involved

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image

Investigators

Thomas Prebet

Principal Investigator

Sub-Investigators